VV

�� !"#$%&'()*+,Incont Pelvic Floor Dysfunct 2009; 3(4):99-103

�� !"#$%&'()*+,-./0

oÉéçêí=Ñêçã=_ÉåáÖå=mêçëí~íáÅ=eóéÉêéä~ëá~LiçïÉê=rêáå~êó=qê~Åí

póãéíçãë=`çããáííÉÉ

��

�� !"#$%&'()

�� !"#$%&'(613�� !"#�!$%&6�� !"#$%&'(�� �� !"#E-mail: cv7589@adm.cgmh.org.tw

��

��

�� !"#$Ebenign prostatic hyperplasia, BPHF�� !"#$

�� !"#$%&'()*+,-./012*+-3456718

�� !"#$�� !"#$%E�� F�� !"#$%&'��

�� !"#$%&'()*+,-./01234567&(89:

�� !"#$%&'()*+,-./0!1230!45167

�� !"#$%&'()*+,-./0123456789$%:

�� !"#$%&'()*+,-./"#0123)456789

�� !"#$%&'()*+,-.%/01

�� !"#$%&'()*+,-./01234��5 67

�� !"#$%&'()*+,��-./0,12345615��

�� !"#$%�&'()*+!,-.*+/012345678

�� !"#$%&'()*+,-./012325�� !"#$%

�� 5�� !"#$ 30�� !"#$%&'()*+,-./ 5

�30�� !"#$%&'()*+,-./0123456789:

�� !"#$%&'()*+,-./01234056789:

�� !"#$%&'()*%+,�-./012%34567%8

��

�� !"#EGuidelinesF�� !

�� !"#$%&'()*+�,-./012340&567

�� !"#$%&'()*+,-./0&12345(6789:

�� !"#$%&'()2005 ICS Jumadilova Z�� !"#$%&

�� !"#$%&'()*Eoveractive bladder, OABF�� !"#$

�� !"#47%�� !"#$%&'("36%�� !"#$%&

�� !"#$%9%�� !"#$%&'()*+8%�� !"#

�� !"#$xPleil, 2005z�� !"#$%&'()*+,-./(

�� !"#$%&'()*+,

�� !"#$

�� !"#$%&!'()*+,-./012345067

�� !"#$%&'()*+,-./0123456789:;<

�� !"#$ %&'()EprostatismF�� !"#$%&'()*

�� !"#$%&'()*+,-./0��123456 7"(

�� !"#$%Ebenign prostatic enlargement, BPEF�� !"#$%

�Ebenign prostatic obstruction, BPOF�� !"#$%&'()*+,)

�� !"�#$%&'()*+,-./012345678,9:

�� !"#$%&'()*+,� !&'(-./001� !"

�� !"#$%&'()*!"Ebladder outlet obstruction, BOOF��

�� !"#$%&'()*+,-./01234567#$%&'

�� !"#$%&'()*+,-.$/012&34"#,56$

�� !"#$%&'()*+,-./0123&,456789:

�� !"#$%& '()*+,- './012345678

�� !"#$%&'()*+,-./012xBarendrecht et al, 2008;

Martin and de la Rosette, 2009z�

�� !"#$%&'()*+,-./0123

�� !"#$%&'()*+,-./0123456789:

�� !"#$%&'()*+,-./0123��456ELUTS

severityF�� !"Ebother scoreF�� !"Edigital rectal examination,

DREF�� !"#$%Eprostate-specific antigen, PSAF�� EurinalysisF

�� !"Evoiding diaryF�� !"#$%&'()*+,-�./0

�� !"#$%&'()*Einternational prostate symptom score, IPSSF

�� � 8�� !"#$%&'()*+,"-./0123Emaxi-

mum flow rate, QmaxF�� !"Eflow patternF�� !Eresidual urineF�

�� AUA�� !"#$%&'()*+',-./012�345

�� !"#$%&'()* 8�� !"#$%&'()*+,-.

�� !"#$%&'()*+,-./01234&5'�67Eα-

blockerF�� !5-α�� �� E5-α reductase inhibitorsF�� !"#

�� !"#$7�� !"#$%&'(Ewatchful waitingF�� !"

�� !

�� !"#$%&'()*+,-68%�� !"#�$%&'

50%�� !"#$%&'()*+,-./01234567289

�� !"#$%&'()*+,-./012)3456789:)

�� !"#$%&'()*+,-./012345 �(6708

�� 5-� �� !"#$%&'()*+,-./01'23!

�� !"#$%&'()EantimuscarinicsF�� !"#$%&'()

�� !�Epostvoid residual urine, PVRF�� !"#$%&'()*!

�� !"#$%&'()*+

�� !"#$%&'()*+,-./0#$12345

EhermaturiaF�� !"#$%&'()�*+�,-�./0123"

��

NMM

�� !"#$%&'()*+,

LUTS cause little or nobother (IPSS< 7)

Predominant nocturia

Frequency volume chart

Reassurance and F/U

Polyuria24-hour output ≥ 3 litersLife style modification

Fluid restriction

Nocturnal polyuria≥ 33% urine output at night

Fluid restrictionConsider desmopressin

SurgeryIndication matched

Recommended test for LUTSMedical history, LUTS severity (IPSS) and

bother score, DRE, PSA, UrinalysisVoiding diary (Option)

Further evaluationBothersome LUTS (IPSS > 8)

Recommended testFlow rate, Residual urine

Optional testSuprapubic echo or TRUS, UDS, Cystoscopy

Suggestive of BPO

SignificantBPO

Mixed OAB andBPO

Depends on size and anatomy of prostateα-blockers + / - 5α- Reductase inhibitors

Failure

Offer minimal invasive surgical treatment or Surgery

Complicated LUTSSuspicious DREHematuriaAbnormal PSAPainInfectionPalpable bladderNeurological disease

OABNo evidence of BOO

Cite OABguideline

First treatmentα-blockers + / -

5α- Reductase inhibitorsSecond treatment

+ / - Antimuscarinics (excludehigh risks)

� NK=�� !"#$%&'()*+,-./0 123456789:;<=

�� !"#$%&'()*+,-./0123456*789:;

�� !"#$

�� Enocturia symptomF�� !"#$%&'()*+,-./

�� !"#$%&'()�*+,-�./01234�5 678

�� !"#$%&'()*+,-.%/01!"234#5�67

�� !"#$%&'()*+,-./*0*1231456'7

EpolyuriaF�� !"#$�%&'()*+,-./0!123456

�� !"#$%&'()*+Enocturnal polyuriaF�� !"#$%&

�� !"#$%&'()*+,-./EdesmopressinF�� E� 1F�

�� !"#$%&

�� !"#$%&'()*+,-E1F�� !"#$%&'()

�� !"#$%&'()*+,-./0 !12345678'9

�� !"#$%&'()*+,-./0xChapple et al , 2008;

Madersbacher et al, 1999; Tong, 2007; Neal et al, 1987z�E2F�� !"#

�� !"#$%Eurinary tract infection, UTIF�� !"#$%&'(

�� !"#$%&$'()*+$,-./E3F�� !"#$%&'

�� !"#$%& !"'()*+ !",-./E4F�� !"#

�� !"#$%&'()*+,-./012,3456"789:

�� Evoiding timeF=�� !"Eflow patternF�� !"#$%&'(

�� !"#$%&'()*+,-. 150 mL�� !"#$%& 15

mL/sec�� !"#$%&' ()*+,-./ 10 mL/sec �� 88%

�� !"#$%&'()*+,-./10-14 mL/sec�� 57%��

�� !"#$%& 15 mL/sec � 33%�� !"#$%xGrino et al,

1993; Siroky et al, 1980; Drach et al, 1979; Abrams, 1977z�E5F��

E u l t r a s o u n d F�� !"#$%&'()*+,-./01234

EcalcificationF�� !"#$%&'()*+,-./012345,'

�� !"#$%&'()*+,-./012'34!5%&'6)

�� !"#$%&'()*+,-./01234#56"789:

�� xDoo and Uh, 2009; Rigatti et al, 2007; Bosch et al, 2008z�E6F��

�� Epressure-flow studyF�� !"#$%&'()*+,-./01

�� !"#$%&'()*+',-'./01234567*8

�� !"#$%&'()*xOelke et al, 2008; Lim et al, 1994; Zhang et

al, 2008; Dib et al, 2008z�

NMN

�� !"#$%&'()*+,

��

��

�� �!

�� !"#$%&'()*+,-./0E1F�� !Eserum

creatinineF�� !"#$%&'()*+,-./01234/56�

�� !"#$% 2%�� !"#$%&'()Esilent renal insuffi-

ciencyF�� !"#$%&'()*+,E2F�� !"#$Eurine

cytologyF�� !"#$%&'()*+,-./012345678

E3F�� !"#$%&'()�*+,-./01210�� !"#$

�� !"#$%&'xMadersbacher et al, 2004; AUA Practice Guidelines

Committee, 2003z�� !"#$%&'()*�+,-.(/0123

�� !"#$%&'()*+,-./01�234%56789:

�� !"#$%&'()�*+,-./0123456789

�� !"#$%&'()*+�� ,-./01234(56

�� !"#$%&$'()*+,-!./$012345,6!.

�� !"#$%&Eacute urinary retention, AURF�� !"#$%&'

�� !"#$%&xRoehrborn, 2000z�� !"#$%&'()*+

25%�� !"#$%&'() !"*+,-./4 ng/mLxPolascik et

al, 1999z�� !"#$%&!'()Evideourodynamic studyF�� !

EcystoscopyF�� !"#$%&'()*+,

�� !

�� !"#$%&'()*+,-./0123456789-

�� !"#$%&'()*+,-. 20%-30%�� !"#$%&

20%-50%�� !"#$%&'()�*+,-./012'34

xClifford and Farmer, 2000; Lowe and Reynolds, 1999; De la Rosette et al,

2 0 0 1 z�� !"#$%&'()*+,-./0123456

Doxazosin�� !"#$%Tamsulosin�� !"#$%&'()*5-

� �� !"#$%&'() Finasteride �� Dutasteride��

�8%�� !"#$%&'()*+,-./012345675-α�

� �� !"#$%&'()(*+$,-./01234$567

�� !"#$%&'()*+xRosen et al, 2005z�

�� !"#$%&'()*+,-.�/0123456789

�� !"#$%&'()*+�,-Eerectile dysfunction, EDF��

�� !"#$%&'()Enon-insulin dependent DM, NIDDMF�� !

�� !"#Echronic renal inusfficiencyF�� !"#$%&'()*+

�� !"#$%&'()*+,-.%/0123456781Modi-

fied-release formulations�� !Alfuzosin�Doxazosin�Tamsulosin�

�� !"#$%&'()*+,-./01*+234"$5%�6

�� !"#$%&'()*+,-./012345 Alfuzosin �

Tamsulosin�� !"#$%&'α1b�adrenergic receptors�� !"

�� !"#$%&'()*#$+,-./01234Tamsulosin�

�� !"#$%&xBarendrecht et al, 2005z�

�� !"#ECombination therapyF

��MTOP�� !"#$%&'()*+,-./01235-α

�� �� !"#$%&'()67%�� !"#$%&'()*+

�� !"#$%&'()xYoung et al, 2002z�� !CombAT��

�� !"#$%&'()*+,-./�0!123456!789

�� !"#$%� !&'()*+,-./012345#678

�� !"#$%&'(�)*CombAT�� !"#$%&'()*

�� !"#$%&'(!")*$+,-./01 !"#$%&'

�� !"#$%&'()*+,-./ 5-� �� Dutasteride

�� !"#Tamsulosin�� !"#$%& 5-� �� !"#

�� !"#$%"&'( 20%-27.3%�� !"#$ 2-6�� !"

�� !"#$%&'()*+,-./012345678901:

�� !"#$%&xMarberger, 1998; McConnell et al, 1998; McConnell

et al, 2003; Roehrborn et al, 2002; Boyle et al, 2004z�� !"#$%!&

�� !"#$%&'()Paul Abrams�Dr. Lee�� !"#$"%

�� !"#$%&'()*+ 3.3%�� !MTOP�� !"#$

�� !4�� !"#$%&'()*+ ,-./012.4%��

�� !"#$%&'()*+,-./+01(23456$789

�� !"#$%&'()*+,-./0123430%-40%�� !

�� !50-150cc�� !"#$%&'()xAbrams et al, 2001; Lee et

al, 2004; Athanasopoulos et al, 2003; Gonzalez and Te, 2003z�

��

�� !"#$%&'()*+,'-./0/1*2345/0

�� !"#$%&'()*+,-.�/ 0123456789:

�� xBlanker et al, 2000z�� !"#$%&'()*+#,-$./

�� !"#$%&'()*+,-./01234567Efrequency-

volume chartF�� !"#�$%!&'()*+,-./01!234

�� !"#$� %&'$()#$*+,-./01� 2345

E� 2F=�

Nocturia

Bothersome?Yes

Exclude

Co-morbidities

Medication effect

Sleep disorder

Environmental problem

Frequency-volume chart

Overactivebladder syndrome

Bladder outflowtract obstruction

Polyuria/nocturnalpolyuria

Rx

No

Rx Rx

Simple advice

� 2K �� !"#$%&'()*+,[Wagg A et al, 2005]�

��

��

��

NMO

�� !"#$%&'()*+,

��

�� !ESurgeryF

�� !Eminimally invasive treatment, MITF�� !"#$%&'

�� !Etrans-urethral microwave thermotherapy, TUMTF�� !"#$

�� !Etrans-urethral needle ablation, TUNAF�� !"Elaser therapyF�

�� !"#$%Egreen light laserF�� !"#$%&'()*+,�

�� !"#$%&'()*+,-./Etrans-urethral resection of

prostate, TURPF�� !"#$% 1992�� !"#$%&'()!

�� !"#2004�� !"#$%&'()*+,-./01234

�� !"#$%1962��2.5%�� !"#0.1%�� !"#$%

1962��18%��11%�� !"#$%&'5.8%�� !"#$%

� 5.6%�� !"#$%&'�(")*+,-! 9.8%�� !"#

�� ! 22%xMartin M, 2009z�

�� !"#$%&'()*500�� !"#$%&'()*+

�� !"#$%&'10%�� !"#$%&'()*+,-./0

�� !"#$%&'()*#+,-./0123456718�9

�� !"#$%&'()*+ 5.2%�� !"#$%6.8%�� !

�� !"#$%&'()*+,-./01234567.89:

�� !"#$%&'()*+,-EAspirinF�� !"#$%&'()

�� !"#$%&'()*+,-./0123456$789:4

�� !"#$%&'()*+,-./012$%&'()3456

�� !"#$%&'()*+,-./012 34 56xRuszat et

al, 2008; Kuntz, 2006 z�

�� !ESelf managementF

�� !"#$%&'(E1F�� !"#$% !&'()*+,

�� !"#$%&' ()*+,-./012()*34+567

�� !"#$%&'()*�+#,)-%&./01)23456

�� !"#E2F�� !"#$%&'()*+�� !, 1500-2000

mL�� !"#$%&'()*+ ,-./01234567 38

�� !"#$%&'()*�#+,-� ./012#3�4+,

�� 2�� !"#$%&'()*+,-E3F�� !"#$%&

�� !"#$%&'()�*+,-."#$/012345E4F��

�� !"#$%&'()* +,-./0/1E5F=�� !"#$%

�� !"#$%&'()*+,� -./012345678&9

�� !"#$%&xBrown et al, 2004; Emberton M, 2006z�

�� !EPrevention therapyF

�� Permixon�Finasteride�� !"#$%&'()*+,-

�� !"Permixon�� !"#$%&'()*+,-./0123

�� !"#$%&'(")*+,-(./0123456Permixon

�� !"#$%&'()*+,-./01 !23456%,-5-

� �� !"#$%&'()*+,-./012345678

�� !"#$%&'�()*+,�-./

�� !

Abrams P, Kaplan S, Millard R: Tolterodine treatment is safe in menwith bladder outlet obstruction (BOO) and symptomatic detrusor

overactivity (DO). Neurourol Urodyn 2001; 20:547-548.Abrams PH: Prostatism and prostatectomy: The value of urine flow rate

measurement in the preoperative assessment for operation. J Urol1977; 117:70-71.

Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P,Barbalias G: Combination treatment with an alpha-blocker plus ananticholinergic for bladder outlet obstruction: A prospective,randomized, controlled study. J Urol 2003; 169:2253-2256.

AUA Practice Guidelines Committee: AUA guideline on management ofbenign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treat-ment recommendations. J Urol 2003; 170:530-547.

Barendrecht MM, Abrams P, Schumacher H, de la Rosette JJ, MichelMC: Do alpha1-adrenoceptor antagonists improve lower urinary tractsymptoms by reducing bladder outlet resistance? Neurourol Urodyn2008; 27:226-230.

Barendrecht MM, Koopmans RP, de la Rosette JJ, Michel MC: Treat-ment of lower urinary tract symptoms suggestive of benign prostatichyperplasia: The cardiovascular system. BJU Int 2005; 95(Suppl 4):19-28.

Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, RuudBosch JL: Normal voiding patterns and determinants of increased di-urnal and nocturnal voiding frequency in elderly men. J Urol 2000;164:1201-1205.

Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM: The long-termrelationship between a real change in prostate volume and a signifi-cant change in lower urinary tract symptom severity in population-basedmen: The Krimpen study. Eur Urol 2008; 53:819-827.

Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, EmbertonM: 5-alpha reductase inhibition provides superior benefits to alphablockade by preventing AUR and BPH-related surgery. Eur Urol 2004;45:620-627.

Brown CT, van der Meulen J, Mundy AR, O'Flynn E, Emberton M: De-fining the components of a self-management programme for men withuncomplicated lower urinary tract symptoms: A consensus approach.Eur Urol 2004; 46:254-263.

Chapple GR, Wein AJ, Abrams P, et al: Lower urinary tract symptomsrevisited: A broder clinical perspective. Eur Urol 2008; 54:563-569.

Clifford GM, Farmer RD: Medical therapy for benign prostatic hyperplasia:A review of the literature. Eur Urol 2000; 38:2-19.

De la Rosette JJ, Alivizatos G, Madersbacher S, et al: EAU Guidelineson benign prostatic hyperplasia (BPH). Eur Urol 2001; 40:256-264.

Dib PT, Trigo-Rocha F, Gomes CM, Srougi M: Urodynamic evaluationin diabetic patients with prostate enlargement and lower urinary tractsymptoms. Urol Int 2008; 80:378-382.

Doo CK, Uh HS: Anatomic configuration of prostate obtained bynoninvasive ultrasonography can predict clinical voiding parametersfor determining BOO in men with LUTS. Urology 2009; 73:232-236.

Drach GW, Layton TN, Binard WJ: Male peak urinary flow rate: Rela-tionships to volume voided and age. J Urol 1979; 122:210-214.

Emberton M: Patient-led management of BPH: From watchful waiting toself-management of LUTS. Eur Urol Suppl 2006; 5:704-709.

Gonzalez RR, Te AE: Overactive bladder and men: Indications foranticholinergics. Curr Urol Rep 2003; 4:429-435.

Grino PB, Bruskewitz R, Blaivas JG, et al: Maximum urinary flow rate byuroflowmetry: Automatic or visual interpretation. J Urol 1993; 149:339-341.

Kuntz RM: Current role of lasers in the treatment of benign prostatichyperplasia (BPH). Eur Urol 2006; 49:961-969.

Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB: Comparisonof doxazosin with or without tolterodine in men with symptomatic blad-der outlet obstruction and an overactive bladder. BJU Int 2004; 94:817-820.

Lim CS, Reynard J, Cannon A, Abrams P: The Abrams-Griffith number:A simple way to quantify bladder outflow obstruction. Neurourol Urodyn1994; 13:475-476.

NMP

�� !"#$%&'()*+,

Lowe PA, Reynolds CR: Age, gender, and education may have littleinfluence on error patterns in the assessment of set-shifting and ruleinduction among normal elderly. Arch Clin Neuropsychol 1999; 14:303-315.

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de laRosette JJ: EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benignprostatic, abstruction (BPH Guidelines). Eur Urol 2004; 46:547-554.

Madersbacher S, Pycha A, Klingler CH, Schatzl G, Marberger M: TheInternational Prostate Symptom score in both sexes: A urodynamics-based comparison. Neurourol Urodyn 1999; 18:173-182.

Marberger MJ: Long-term effects of Finasteride in patients with benignprostatic hyperplasia: A double-blind, placebo-controlled, multicenterstudy. Urology 1998; 51:677-686.

Martin M, de la Rosette J: Medical treatment of lower urinary tract symp-toms suggestive of benign prostatic hyperplasia. Eur Urol Suppl 2009;8:496-503.

McConnell JD, Bruskewitz R, Walsh P, et al: The effect of Finasterideon the risk of acute urinary retention and the need for surgical treat-ment among men with benign prostatic hyperplasia. N Engl J Med1998; 338:557-563.

McConnell JD, Roehrborn CG, Bautista OM, et al: The long-term effectof Doxazosin, Finasteride, and combination therapy on the clinical pro-gression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.

Neal DE, Styles RA, Powell PH, Ramsden PD: Relationship betweendetrusor function and residual urine in men undergoing prostatectomy.Br J Urol 1987; 60:560-566.

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hofner K: Ageand bladder outlet obstruction are independently associated with de-trusor overactivity in patients with benign prostatic hyperplasia. EurUrol 2008; 54:419-426.

Pleil A, Coyne K, Reese P, Jumadilova, Z, Kellehe C: Confirming thevalidity of patient global impression's as outcome measures in overac-tive bladder. Eur Urol Suppl 2005; 4:142.

Polascik TJ, Oesterling JE, Partin AW: Prostate-specific antigen: A de-cade of discovery - What we have learned and where we are going. JUrol 1999; 162:293-306.

Rigatti P, Cestari A, Gilling P: The motion: Large BPH should be treatedby open surgery. Eur Urol 2007; 51:845-848.

Roehrborn CG, Bruskewitz R, Nickel GC, et al: Urinary retention in pa-tients with BPH treated with Finasteride or placebo over 4 years.Char-acterization of patients and ultimate outcomes. The PLESS StudyGroup. Eur Urol 2000; 37:528-536.

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G: Efficacy andsafety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride)in men with benign prostatic hyperplasia. Urology 2002; 60:434-441.

Ruszat R, Seitz M, Wyler SF, et al: GreenLight laser vaporization of theprostate: Single-center experience and long-term results after 500procedures. Eur Urol 2008; 54:893-901.

Rosen RC, Giuliano F, Carson CC: Sexual dysfunction and lower uri-nary tract symptoms (LUTS) associated with benign prostatic hyper-plasia (BPH). Eur Urol 2005; 47:824-837.

Siroky MB, Olsson CA, Krane RJ: The flow rate nomogram: II. Clinicalcorrelation. J Urol 1980; 123:208-210.

Tong YC: Comparisons of urodynamic findings and voiding habits inpatients with concomitant benign prostatic hyperplasia and detrusoroveractivity presenting with or without the symptom of urgency. UrolInt 2007; 78:219-225.

Wagg A, Andersson K-E, Cardozo L, et al: Nocturia: Morbidity and man-agement in adults. Int J Clin Pract 2005; 59:938-945.

Young HH, Frontz WA, Baldwin JC: Congenital obstruction of the poste-rior urethra. J Urol, 3: 289-365, 1919. J Urol 2002; 167:265-268.

Zhang K, Xu Z, Zhang J, Wang H, Zhang D, Shi B: Clinical significanceof urodynamic analysis in patients with benign prostatic enlargementcomplicated with diabetes mellitus. Urol Int 2008; 81:149-152.